Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational

Hemostatic Profiles in Pediatric CKD

NCT05064267
Conditions
Kidney Disease, Chronic, Pediatric Kidney Disease, Renal Insufficiency, Chronic, Blood Coagulation Disorders in Children
Interventions
phlebotomy
Diagnostic Test
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
6 Months to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Coagulopathy
Interventions
Thromboelastography (TEG 6S)
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
3 Months to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Terminated Phase 3 Interventional Results available

Early Prophylaxis Immunologic Challenge (EPIC) Study

NCT01376700
Conditions
Hemophilia A
Interventions
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Up to 1 Year · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • New Brunswick, New Jersey
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions
Laboratory clotting studies
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
0 Hours to 2 Hours
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Hemophilia A
Interventions
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC), Emicizumab
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Coagulation Disorder, Bleeding
Interventions
Coagulation Laboratory Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of Novel Point of Care Coagulation System in Pregnant Women

NCT04301193
Conditions
Hemorrhage, Coagulation Delay
Interventions
Quantra Analyzer
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Burn, Coagulation, Blood
Interventions
Thromboelastography
Diagnostic Test
Lead sponsor
Francesco Egro
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Conditions
Pancreaticoduodenectomy, Hepatectomy
Interventions
Normovolemic Hemodilution (ANH), Standard of care
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers Results available

Coagulation Factor Changes Associated With Postpartum Hysterectomies

NCT00456547
Conditions
Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Anal Cancer, High-grade Squamous Intraepithelial Lesion, HIV Infection, Human Papilloma Virus Infection
Interventions
imiquimod, fluorouracil, infrared photocoagulation therapy, thermal ablation therapy, laser therapy, clinical observation, laboratory biomarker analysis
Drug · Device · Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
35 Years and older
Enrollment
4,446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
24
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 13 more
Not listed No phase listed Observational

Low VW Activity in Adolescent HMB

NCT02933411
Conditions
Von Willebrand Factor Deficiency
Interventions
Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
Conditions
Obesity, Obesity, Morbid, Obesity; Endocrine, Bariatric Surgery Candidate
Interventions
Gastric mucosal devitalization
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
28 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
Interventions
Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Conditions
Arthralgia, Musculoskeletal Complications, Pain, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
letrozole, calcium carbonate, laboratory biomarker analysis, calcium citrate, calcium glucarate, calcium gluconate, cholecalciferol, assessment of therapy complications, musculoskeletal complications management/prevention
Drug · Dietary Supplement · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Hypersomnia
Interventions
Low Sodium Oxybate, 24-hour polysomnography, Nextsense EEG earbuds, Axivity device
Drug · Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Conditions
Healthy
Interventions
TEG 6s Citrated K, KH, RTH, and FFH Cartridge, Clauss Fibrinogen
Diagnostic Test
Lead sponsor
Haemonetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Oakland, California • Maywood, Illinois • New Orleans, Louisiana
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acquired Hemophilia A
Interventions
OBIZUR
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Gainesville, Florida • Detroit, Michigan • Durham, North Carolina + 2 more
Conditions
Breast Cancer
Interventions
Taking Charge during Treatment (TCT) Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Wauwatosa, Wisconsin
Conditions
Neuromuscular Scoliosis
Interventions
Thromboelastography laboratory testing
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts